ReviewHepatic medicine : evidence and research2012
Epidemiology and treatment of autoimmune hepatitis.
Review in Hepatic medicine : evidence and research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes.Clinical and experimental immunology · 2021Trial
- Fasudil Attenuates Concanavalin A-Induced Autoimmune Hepatitis and Is Associated with Suppression of RhoA/ROCK and TLR4/NF-κB Signaling and Modulation of Immune Responses.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Late-onset combined immunodeficiency and bone marrow failure in severe autoimmune hepatitis: a case report.Journal of medical case reports · 2026Article
- Immediate management of a cirrhosis-induced severe pericardial effusion: a case report and review of the literature.Journal of medical case reports · 2025Review
- 6-Formylindolo[3,2-b]carbazole, a potent ligand for the aryl hydrocarbon receptor, attenuates concanavalin-induced hepatitis by limiting T-cell activation and infiltration of proinflammatory CD11b+ Kupffer cells.Journal of leukocyte biology · 2024Article
- Updated consensus guidelines on the management of Phelan-McDermid syndrome.American journal of medical genetics. Part A · 2023Review
- Clinical Characteristics of Autoimmune Hepatitis in a Middle Eastern Population: A Tertiary Care Center Experience.Journal of clinical medicine · 2023Article
- Construction and function analysis of the LncRNA-miRNA-mRNA competing endogenous RNA network in autoimmune hepatitis.BMC medical genomics · 2022Article
- Escin suppresses immune cell infiltration and selectively modulates Nrf2/HO-1, TNF-α/JNK, and IL-22/STAT3 signaling pathways in concanavalin A-induced autoimmune hepatitis in mice.Inflammopharmacology · 2022Article
- Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns.Acta pharmaceutica Sinica. B · 2021Review
- Etiopathogenesis and Diagnostic Strategies in Autoimmune Hepatitis.Diagnostics (Basel, Switzerland) · 2021Review
- Autoconversion of Autoimmune Liver Diseases.Digestive diseases and sciences · 2020Review
- [Severe acquired marrow aplasia and seronegative autoimmune hepatitis: a rare and serious association].The Pan African medical journal · 2019Article
- The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2018Article
- Differential Diagnosis of Hepatic Necrosis Encountered at Autopsy.Academic forensic pathology · 2018Review
- Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis.World journal of gastroenterology · 2017Article
- Seronegative Autoimmune Hepatitis A Clinically Challenging Difficult Diagnosis.Case reports in medicine · 2017Article
- Magnetic resonance imaging findings in autoimmune hepatitis: how frequent and reproducible are they?Radiologia brasileiraArticle
- Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hepatitis (AIH) is a chronic inflammatory disease of the liver that occurs worldwide with a low and probably underestimated prevalence. Although it typically affects young and middle-aged women, it can occur in both sexes and across all age groups. AIH runs a fluctuating course, but can present as severe and even fulminant hepatic failure or at a stage of advanced fibrosis or cirrhosis. Prognosis of severe AIH is poor if untreated. The pathogenesis is complex, combining environmental factors (external chemical or infectious triggers) and host genetic susceptibility. The diagnosis is based, after exclusion of other etiologies of chronic liver disease, on a combination of different elements, including the presence of elevated transaminases, elevated immunoglobulin G (IgG) levels, the presence and pattern of typical autoantibodies, and a liver biopsy showing interface hepatitis and other characteristic features. No single test can be used to make the diagnosis. Response to treatment can also help to establish the diagnosis. Simplified criteria can be used to make a bedside diagnosis with relatively high accuracy. Treatment consists of corticosteroids or other immunosuppressive regimens according to the severity of the disease, the response to the treatment, and the tolerance to therapy, with liver transplantation as an ultimate remedy in treatment-resistant cases with liver decompensation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.